India is in the final phases of developing a clinical trial protocol for convalescent plasma therapy that uses antibodies from either the blood of recovered patients to treat serious COVID-19 patients, a senior ICMR official said.
Kerala is expected to be the first state in the country to launch the therapy on a trial basis for treating those critically ill.
For the first project of its kind, initiated by the prestigious Sree Chitra Tirunal Institute for Medical Sciences and Technology (SCTIMST), a top official had said, the ICMR learned to give its nod to the state government.
On Thursday, the ICMR official said they’d need permission from India’s Drug Controller General (DCGI) before undertaking on any clinical study using the medication.
He said it isn’t currently being used or recommended in India for patients.
“We will be in the early stages of developing a procedure for nursing home plasma therapy and then we will require DCGI approval. So far it will only be used in clinical trials,” he said, adding that perhaps the therapy has been effective in small clinical trials in some countries on patients in serious condition or on ventilator support.
The death count related to the novel coronavirus went up to 199 and on Friday, according to the Union Health Ministry, the number of cases climbed to 6,640 in the world.
Moreover, as on Thursday late evening, a PTI tally of figures recorded by different states showed at least 6640 cases and 227 deaths.
There is a discrepancy in the statistics from the number of cases declared by various states in the Union Health Ministry that officials relate bureaucratic delays in identifying the cases to specific states.